Shopping Cart 0
Cart Subtotal
USD 0

OpportunityAnalyzer: Ovarian Cancer-Opportunity Analysis and Forecasts to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 10995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 21990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 32985

Details

OpportunityAnalyzer: Ovarian Cancer-Opportunity Analysis and Forecasts to 2025

Summary

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered

How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?

What are the most promising late-stage pipeline drugs in ovarian cancer?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the unmet needs in ovarian cancer treatment management?

What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Ovarian Cancer: Executive Summary 10

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025 10

2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers 12

2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM's Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer's First-to-Market Bavencio 13

2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining 14

2.5 What Do Physicians Think? 16

3 Introduction 20

3.1 Catalyst 20

3.2 Related Reports 21

3.3 Upcoming Related Reports 21

4 Disease Overview 22

4.1 Etiology and Pathophysiology 22

4.2 Staging Systems 23

4.3 Risk Factors, Symptoms, and Screening 24

4.4 Prognosis and Quality of Life 26

5 Epidemiology 28

5.1 Disease Background 28

5.2 Risk Factors and Comorbidities 28

5.3 Global Trends 30

5.3.1 7MM Incidence Trends 30

5.3.2 7MM Trends in Relative Survival 30

5.4 Forecast Methodology 31

5.4.1 Sources Used Tables 31

5.4.2 Forecast Assumptions and Methods 32

5.4.3 Sources Not Used 34

5.5 Epidemiological Forecast for Ovarian Cancer (2015-2025) 35

5.5.1 Diagnosed Incident Cases of Ovarian Cancer 35

5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer 37

5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer 38

5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer 39

5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer 41

5.6 Discussion 42

5.6.1 Epidemiological Forecast Insight 42

5.6.2 Limitations of the Analysis 42

5.6.3 Strengths of the Analysis 43

6 Current Treatment Options 44

6.1 Overview 44

6.2 Diagnosis and Treatment 44

6.2.1 Diagnosis 44

6.2.2 Treatment Guidelines 45

6.3 Clinical Practice and Leading Prescribed Drugs 46

6.4 Product Profiles-Major Brands, Angiogenesis Inhibitors 50

6.4.1 Avastin (bevacizumab) 50

6.5 Product Profiles-Major Brands, PARP Inhibitors 59

6.5.1 Lynparza (olaparib) 60

6.5.2 Rubraca (rucaparib) 70

6.5.3 Zejula (niraparib) 75

6.6 Product Profiles-Major Brands, Next-Generation Chemotherapies 81

6.6.1 Yondelis (trabectedin) 81

6.7 Generic Chemotherapy 87

6.7.1 Front-Line Treatment (Adjuvant/First Line) 87

6.7.2 Recurrent Disease 92

7 Unmet Needs Assessment and Opportunity Analysis 95

7.1 Overview 95

7.2 Improved First-line Therapies 96

7.2.1 Unmet Need 96

7.2.2 Gap Analysis 96

7.2.3 Opportunity 99

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients 99

7.3.1 Unmet Need 99

7.3.2 Gap Analysis 100

7.3.3 Opportunity 101

7.4 Individualized Treatment Approaches 102

7.4.1 Unmet Need 102

7.4.2 Gap Analysis 102

7.4.3 Opportunity 104

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer 104

7.5.1 Unmet Need 104

7.5.2 Gap Analysis 105

7.5.3 Opportunity 105

7.6 An Early Stage Diagnostic for Ovarian Cancer 105

7.6.1 Unmet Need 105

7.6.2 Gap Analysis 106

7.6.3 Opportunity 106

8 Research and Development Strategies 107

8.1 Overview 107

8.1.1 Optimizing Chemotherapy 108

8.1.2 Targeted Therapies-A Patient Specific Approach 109

8.1.3 Immunotherapies-A Patient Specific Approach 114

8.1.4 Combination Therapies 116

8.1.5 Licenses and Alliances 117

8.2 Clinical Trial Design 118

8.2.1 Current Clinical Trial Endpoints 120

8.2.2 The Future of Clinical Trial Endpoints 120

8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials 121

9 Pipeline Assessment 124

9.1 Overview 124

9.2 Product Profiles-Immune Checkpoint Modulators 126

9.2.1 Bavencio (avelumab) 128

9.2.2 Opdivo (nivolumab) 134

9.2.3 Tecentriq (atezolizumab) 139

9.3 Product Profiles-Cancer Vaccines 144

9.3.1 Vigil (gemogenovatucel-T) 144

9.4 Product Profiles-Vascular Disrupting Agents 150

9.4.1 Fosbretabulin tromethamine 150

9.5 Product Profiles-PARP Inhibitors 155

9.5.1 Veliparib 157

9.6 Product Profiles-Targeted Cytotoxic Therapies (Antibody-Drug Conjugates) 163

9.6.1 Mirvetuximab soravtansine 163

9.7 Product Profiles-Next-Generation Chemotherapies 168

9.7.1 Opaxio (paclitaxel poliglumex) 168

9.7.2 Lurbinectedin 174

9.7.3 Apealea/Paclical (paclitaxel) 178

9.8 Innovative Early Stage Approaches 182

9.8.1 Immune Checkpoint Modulators 183

9.8.2 Oncolytic Viruses 188

9.8.3 Angiogenesis Inhibitors 191

9.8.4 Interleukin-12 Agonists 194

9.8.5 Toll-Like Receptor 8 Agonists 195

9.8.6 Cancer Vaccines 196

9.8.7 Kinase Inhibitors 199

9.8.8 Targeted Cytotoxic Therapies 203

9.8.9 P53 Agonists 203

9.9 Other Notable Drugs in Clinical Development 204

10 Pipeline Valuation Analysis 206

10.1 Clinical Benchmark of Key Pipeline Products 206

10.2 Commercial Benchmark of Key Pipeline Therapies 209

10.3 Competitive Assessment 210

10.4 Top-Line Ten-Year Forecast 212

10.4.1 US 216

10.4.2 5EU 217

10.4.3 Japan 218

11 Appendix 220

11.1 Bibliography 220

11.2 Abbreviations 247

11.3 Methodology 254

11.4 Forecasting Methodology 254

11.4.1 Percentage of Drug-Treated Patients 255

11.4.2 Drugs Included in Each Therapeutic Class 256

11.4.3 Launch and Patent Expiry Dates 256

11.4.4 General Pricing Assumptions 257

11.4.5 Average Body Weight and Surface Area Across the 7MM 258

11.4.6 General Forecast Assumptions 258

11.4.7 Individual Drug Assumptions 259

11.4.8 Generic and Biosimilar Erosion 266

11.4.9 Pricing of Pipeline Agents 266

11.5 Primary Research 274

11.5.1 Physicians and Specialists Included in This Study 274

11.5.2 Online Survey of High-Prescribing Physicians 276

11.6 About the Authors 277

11.6.1 Analysts 277

11.6.2 Epidemiologist 278

11.6.3 Therapy Area Director 278

11.6.4 Global Director of Therapy Analysis and Epidemiology 278

11.6.5 Global Head of Healthcare 279

11.7 About GlobalData 279

11.8 Contact Us 280

11.9 Disclaimer 280


List Of Figure

1.2 List of Figures

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025 12

Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 15

Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms 23

Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer 25

Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998?2007 30

Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025 36

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 38

Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages?18 Years, Cases per 100,000, 2015 39

Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025 40

Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025 42

Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients 48

Figure 12: Clinical Development Program for Avastin in Ovarian Cancer 53

Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer 63

Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer 72

Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer 78

Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer 83

Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer 131

Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer 136

Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer 142

Figure 20: Clinical Development Program for Vigil in Ovarian Cancer 148

Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer 153

Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer 160

Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer 165

Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer 170

Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer 175

Figure 26: Clinical Development Program for Apealea in Ovarian Cancer 180

Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer 192

Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 211

Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025 214


List Of Table

1.1 List of Tables

Table 1: Ovarian Cancer: Key Metrics in the 7MM 10

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum 24

Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016 26

Table 4: Risk Factors of OC 29

Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC 31

Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC 32

Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025 35

Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 37

Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025 40

Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025 41

Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM 45

Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease 49

Table 13: Product Profile-Avastin 51

Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 56

Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer 57

Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer 57

Table 17: Grade ?3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer 58

Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017 58

Table 19: Product Profile-Lynparza 61

Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial 65

Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer 66

Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer 67

Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19 68

Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017 69

Table 25: Product Profile-Rubraca 70

Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer 73

Table 27: Most Common AEs Reported in ?20% of Patients in Study 10 and ARIEL2 74

Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017 74

Table 29: Product Profile-Zejula 76

Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer 79

Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula 80

Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017 81

Table 33: Product Profile-Yondelis 82

Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer 85

Table 35: Most Commonly Reported Grade 3 and 4 AEs in ?5% of Patients in OVA-301 86

Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017 87

Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer 88

Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer 89

Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer 90

Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment 91

Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer 94

Table 42: Unmet Needs and Opportunities in Ovarian Cancer 96

Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer. 118

Table 44: Potential New Classification System for Recurrent Ovarian Cancer 123

Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017 125

Table 46: Product Profile-Bavencio 129

Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 132

Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 132

Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 133

Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 133

Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017 134

Table 52: Product Profile-Opdivo 135

Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714) 137

Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo 138

Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017 139

Table 56: Product Profile-Tecentriq 140

Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017 144

Table 58: Product Profile-Vigil (gemogenovatucel-T) 146

Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial 149

Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials 149

Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017 150

Table 62: Product Profile-Fosbretabulin Tromethamine 152

Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer 154

Table 64: Grade ?2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer 154

Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017 155

Table 66: Product Profile-Veliparib 158

Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 161

Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial 162

Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017 162

Table 70: Product Profile-Mirvetuximab soravtansine 164

Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer 166

Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer 167

Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017 167

Table 74: Product Profile-Opaxio 169

Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer 172

Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer 173

Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017 173

Table 78: Product Profile-Lurbinectedin 174

Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer 177

Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer 177

Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017 178

Table 82: Product Profile-Apealea 179

Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer 181

Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer 181

Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017 182

Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017 183

Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy 184

Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda 185

Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab 186

Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat 187

Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab 188

Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin 189

Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev 190

Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer 193

Table 95: Summary of Grade ?3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer 194

Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017 194

Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1 195

Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod 196

Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac 197

Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa 198

Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac 199

Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib 200

Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef 201

Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib 202

Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib 203

Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027 203

Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246 204

Table 108: Other Notable Ovarian Cancer Products in Development, 2017 205

Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products 207

Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued 207

Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products 210

Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued 210

Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015-2025 ($M) 213

Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015-2025 215

Table 115: Ovarian Cancer Products Market-Drivers and Barriers, 2015-2025 216

Table 116: Ovarian Cancer Patient Population segmentations in the 7MM-Secondary Sources Leveraged 255

Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class 256

Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM 256

Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM 257

Table 120: Average Body Weight and Surface Area Across the 7MM 258

Table 121: Average Cost of Therapy of Avastin in the 7MM 261

Table 122: Average Cost of Therapy of Lynparza in the 7MM 263

Table 123: Average Cost of Therapy of Rubraca in the US and 5EU 264

Table 124: Average Cost of Therapy of Yondelis in the 7MM 265

Table 125: Average Cost of Therapy of Votrient in the 7MM 265

Table 126: Average Cost of Therapy of Zejula in the US and 5EU 266

Table 127: Average Cost of Therapy of Veliparib in the 7MM 267

Table 128: Average Cost of Therapy of Bavencio in the 7MM 268

Table 129: Average Cost of Therapy of Tecentriq in the 7MM 269

Table 130: Average Cost of Therapy of Opdivo in the 7MM 270

Table 131: Average Cost of Therapy of Vigil in the 7MM 270

Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM 271

Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU 272

Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM 273

Table 135: Average Cost of Therapy of Apealea in the US and 5EU 274

Table 136: High-Prescribing Physicians Surveyed, by Country 277

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

OpportunityAnalyzer: Ovarian Cancer-Opportunity Analysis and Forecasts to 2025

Summary

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered

How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?

What are the most promising late-stage pipeline drugs in ovarian cancer?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the unmet needs in ovarian cancer treatment management?

What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Ovarian Cancer: Executive Summary 10

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025 10

2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers 12

2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM's Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer's First-to-Market Bavencio 13

2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining 14

2.5 What Do Physicians Think? 16

3 Introduction 20

3.1 Catalyst 20

3.2 Related Reports 21

3.3 Upcoming Related Reports 21

4 Disease Overview 22

4.1 Etiology and Pathophysiology 22

4.2 Staging Systems 23

4.3 Risk Factors, Symptoms, and Screening 24

4.4 Prognosis and Quality of Life 26

5 Epidemiology 28

5.1 Disease Background 28

5.2 Risk Factors and Comorbidities 28

5.3 Global Trends 30

5.3.1 7MM Incidence Trends 30

5.3.2 7MM Trends in Relative Survival 30

5.4 Forecast Methodology 31

5.4.1 Sources Used Tables 31

5.4.2 Forecast Assumptions and Methods 32

5.4.3 Sources Not Used 34

5.5 Epidemiological Forecast for Ovarian Cancer (2015-2025) 35

5.5.1 Diagnosed Incident Cases of Ovarian Cancer 35

5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer 37

5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer 38

5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer 39

5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer 41

5.6 Discussion 42

5.6.1 Epidemiological Forecast Insight 42

5.6.2 Limitations of the Analysis 42

5.6.3 Strengths of the Analysis 43

6 Current Treatment Options 44

6.1 Overview 44

6.2 Diagnosis and Treatment 44

6.2.1 Diagnosis 44

6.2.2 Treatment Guidelines 45

6.3 Clinical Practice and Leading Prescribed Drugs 46

6.4 Product Profiles-Major Brands, Angiogenesis Inhibitors 50

6.4.1 Avastin (bevacizumab) 50

6.5 Product Profiles-Major Brands, PARP Inhibitors 59

6.5.1 Lynparza (olaparib) 60

6.5.2 Rubraca (rucaparib) 70

6.5.3 Zejula (niraparib) 75

6.6 Product Profiles-Major Brands, Next-Generation Chemotherapies 81

6.6.1 Yondelis (trabectedin) 81

6.7 Generic Chemotherapy 87

6.7.1 Front-Line Treatment (Adjuvant/First Line) 87

6.7.2 Recurrent Disease 92

7 Unmet Needs Assessment and Opportunity Analysis 95

7.1 Overview 95

7.2 Improved First-line Therapies 96

7.2.1 Unmet Need 96

7.2.2 Gap Analysis 96

7.2.3 Opportunity 99

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients 99

7.3.1 Unmet Need 99

7.3.2 Gap Analysis 100

7.3.3 Opportunity 101

7.4 Individualized Treatment Approaches 102

7.4.1 Unmet Need 102

7.4.2 Gap Analysis 102

7.4.3 Opportunity 104

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer 104

7.5.1 Unmet Need 104

7.5.2 Gap Analysis 105

7.5.3 Opportunity 105

7.6 An Early Stage Diagnostic for Ovarian Cancer 105

7.6.1 Unmet Need 105

7.6.2 Gap Analysis 106

7.6.3 Opportunity 106

8 Research and Development Strategies 107

8.1 Overview 107

8.1.1 Optimizing Chemotherapy 108

8.1.2 Targeted Therapies-A Patient Specific Approach 109

8.1.3 Immunotherapies-A Patient Specific Approach 114

8.1.4 Combination Therapies 116

8.1.5 Licenses and Alliances 117

8.2 Clinical Trial Design 118

8.2.1 Current Clinical Trial Endpoints 120

8.2.2 The Future of Clinical Trial Endpoints 120

8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials 121

9 Pipeline Assessment 124

9.1 Overview 124

9.2 Product Profiles-Immune Checkpoint Modulators 126

9.2.1 Bavencio (avelumab) 128

9.2.2 Opdivo (nivolumab) 134

9.2.3 Tecentriq (atezolizumab) 139

9.3 Product Profiles-Cancer Vaccines 144

9.3.1 Vigil (gemogenovatucel-T) 144

9.4 Product Profiles-Vascular Disrupting Agents 150

9.4.1 Fosbretabulin tromethamine 150

9.5 Product Profiles-PARP Inhibitors 155

9.5.1 Veliparib 157

9.6 Product Profiles-Targeted Cytotoxic Therapies (Antibody-Drug Conjugates) 163

9.6.1 Mirvetuximab soravtansine 163

9.7 Product Profiles-Next-Generation Chemotherapies 168

9.7.1 Opaxio (paclitaxel poliglumex) 168

9.7.2 Lurbinectedin 174

9.7.3 Apealea/Paclical (paclitaxel) 178

9.8 Innovative Early Stage Approaches 182

9.8.1 Immune Checkpoint Modulators 183

9.8.2 Oncolytic Viruses 188

9.8.3 Angiogenesis Inhibitors 191

9.8.4 Interleukin-12 Agonists 194

9.8.5 Toll-Like Receptor 8 Agonists 195

9.8.6 Cancer Vaccines 196

9.8.7 Kinase Inhibitors 199

9.8.8 Targeted Cytotoxic Therapies 203

9.8.9 P53 Agonists 203

9.9 Other Notable Drugs in Clinical Development 204

10 Pipeline Valuation Analysis 206

10.1 Clinical Benchmark of Key Pipeline Products 206

10.2 Commercial Benchmark of Key Pipeline Therapies 209

10.3 Competitive Assessment 210

10.4 Top-Line Ten-Year Forecast 212

10.4.1 US 216

10.4.2 5EU 217

10.4.3 Japan 218

11 Appendix 220

11.1 Bibliography 220

11.2 Abbreviations 247

11.3 Methodology 254

11.4 Forecasting Methodology 254

11.4.1 Percentage of Drug-Treated Patients 255

11.4.2 Drugs Included in Each Therapeutic Class 256

11.4.3 Launch and Patent Expiry Dates 256

11.4.4 General Pricing Assumptions 257

11.4.5 Average Body Weight and Surface Area Across the 7MM 258

11.4.6 General Forecast Assumptions 258

11.4.7 Individual Drug Assumptions 259

11.4.8 Generic and Biosimilar Erosion 266

11.4.9 Pricing of Pipeline Agents 266

11.5 Primary Research 274

11.5.1 Physicians and Specialists Included in This Study 274

11.5.2 Online Survey of High-Prescribing Physicians 276

11.6 About the Authors 277

11.6.1 Analysts 277

11.6.2 Epidemiologist 278

11.6.3 Therapy Area Director 278

11.6.4 Global Director of Therapy Analysis and Epidemiology 278

11.6.5 Global Head of Healthcare 279

11.7 About GlobalData 279

11.8 Contact Us 280

11.9 Disclaimer 280


List Of Figure

1.2 List of Figures

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025 12

Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 15

Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms 23

Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer 25

Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998?2007 30

Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025 36

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 38

Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages?18 Years, Cases per 100,000, 2015 39

Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025 40

Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025 42

Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients 48

Figure 12: Clinical Development Program for Avastin in Ovarian Cancer 53

Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer 63

Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer 72

Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer 78

Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer 83

Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer 131

Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer 136

Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer 142

Figure 20: Clinical Development Program for Vigil in Ovarian Cancer 148

Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer 153

Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer 160

Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer 165

Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer 170

Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer 175

Figure 26: Clinical Development Program for Apealea in Ovarian Cancer 180

Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer 192

Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017 211

Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025 214


List Of Table

1.1 List of Tables

Table 1: Ovarian Cancer: Key Metrics in the 7MM 10

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum 24

Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016 26

Table 4: Risk Factors of OC 29

Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC 31

Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC 32

Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ?18 Years, N, 2015-2025 35

Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015 37

Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ?18 Years, N, 2015-2025 40

Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ?18 Years, N, 2015-2025 41

Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM 45

Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease 49

Table 13: Product Profile-Avastin 51

Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 56

Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer 57

Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer 57

Table 17: Grade ?3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer 58

Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017 58

Table 19: Product Profile-Lynparza 61

Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial 65

Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer 66

Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer 67

Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19 68

Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017 69

Table 25: Product Profile-Rubraca 70

Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer 73

Table 27: Most Common AEs Reported in ?20% of Patients in Study 10 and ARIEL2 74

Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017 74

Table 29: Product Profile-Zejula 76

Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer 79

Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula 80

Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017 81

Table 33: Product Profile-Yondelis 82

Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer 85

Table 35: Most Commonly Reported Grade 3 and 4 AEs in ?5% of Patients in OVA-301 86

Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017 87

Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer 88

Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer 89

Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer 90

Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment 91

Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer 94

Table 42: Unmet Needs and Opportunities in Ovarian Cancer 96

Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer. 118

Table 44: Potential New Classification System for Recurrent Ovarian Cancer 123

Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017 125

Table 46: Product Profile-Bavencio 129

Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 132

Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 132

Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015 133

Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016 133

Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017 134

Table 52: Product Profile-Opdivo 135

Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714) 137

Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo 138

Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017 139

Table 56: Product Profile-Tecentriq 140

Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017 144

Table 58: Product Profile-Vigil (gemogenovatucel-T) 146

Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial 149

Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials 149

Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017 150

Table 62: Product Profile-Fosbretabulin Tromethamine 152

Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer 154

Table 64: Grade ?2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer 154

Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017 155

Table 66: Product Profile-Veliparib 158

Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer 161

Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial 162

Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017 162

Table 70: Product Profile-Mirvetuximab soravtansine 164

Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer 166

Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FR?+ Ovarian Cancer 167

Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017 167

Table 74: Product Profile-Opaxio 169

Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer 172

Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer 173

Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017 173

Table 78: Product Profile-Lurbinectedin 174

Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer 177

Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer 177

Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017 178

Table 82: Product Profile-Apealea 179

Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer 181

Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer 181

Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017 182

Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017 183

Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy 184

Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda 185

Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab 186

Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat 187

Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab 188

Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin 189

Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev 190

Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer 193

Table 95: Summary of Grade ?3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer 194

Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017 194

Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1 195

Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod 196

Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac 197

Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa 198

Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac 199

Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib 200

Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef 201

Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib 202

Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib 203

Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027 203

Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246 204

Table 108: Other Notable Ovarian Cancer Products in Development, 2017 205

Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products 207

Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued 207

Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products 210

Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued 210

Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015-2025 ($M) 213

Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015-2025 215

Table 115: Ovarian Cancer Products Market-Drivers and Barriers, 2015-2025 216

Table 116: Ovarian Cancer Patient Population segmentations in the 7MM-Secondary Sources Leveraged 255

Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class 256

Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM 256

Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM 257

Table 120: Average Body Weight and Surface Area Across the 7MM 258

Table 121: Average Cost of Therapy of Avastin in the 7MM 261

Table 122: Average Cost of Therapy of Lynparza in the 7MM 263

Table 123: Average Cost of Therapy of Rubraca in the US and 5EU 264

Table 124: Average Cost of Therapy of Yondelis in the 7MM 265

Table 125: Average Cost of Therapy of Votrient in the 7MM 265

Table 126: Average Cost of Therapy of Zejula in the US and 5EU 266

Table 127: Average Cost of Therapy of Veliparib in the 7MM 267

Table 128: Average Cost of Therapy of Bavencio in the 7MM 268

Table 129: Average Cost of Therapy of Tecentriq in the 7MM 269

Table 130: Average Cost of Therapy of Opdivo in the 7MM 270

Table 131: Average Cost of Therapy of Vigil in the 7MM 270

Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM 271

Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU 272

Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM 273

Table 135: Average Cost of Therapy of Apealea in the US and 5EU 274

Table 136: High-Prescribing Physicians Surveyed, by Country 277

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS